Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Primary objective To estimate 6-month progression free survival probability of pts w
recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on
bev + irinotecan Secondary Objectives To evaluate safety & tolerability of bev + either daily
temozolomide/etoposide among pts w recurrent GBM who have progressed on bev + irinotecan To
evaluate radiographic response, progression free survival & overall survival of pts w
recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on
bev + irinotecan